
Michael W Fried MD FAASLD
Hepatology & Liver Transplantation
Professor of Medicine, University of North Carolina School of Medicine
Join to view full profile
University of North Carolina101 Manning DriveChapel Hill, NC 27514
Phone+1 919-843-6386
Dr. Fried is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Michael W. Fried, MD, FAASLD
is Professor of Medicine and Director of Hepatology at the University of North Carolina (UNC) at Chapel Hill. Dr. Fried served as President of the American Association for the Study of Liver Diseases (AASLD) in 2019. He completed his internship and residency in internal medicine at the State University of New York (SUNY) Health Science Center at Syracuse, where he also completed a fellowship in gastroenterology.
From 1990 to 1993, while serving as Medical Staff Fellow in the Liver Diseases Section at the National Institutes of Health (NIH) in Bethesda, Maryland, Dr. Fried performed clinical and laboratory studies of viral hepatitis. During his tenure at UNC, he has been the principal investigator on numerous clinical trials of antiviral agents for chronic hepatitis B and hepatitis C. Dr. Fried has been awarded continuous NIH extramural funding for over 20 years as principal investigator on several NIH cooperative clinical trials and he currently serves as the co-chair of the Hepatitis B Research Network (NIDDK). Most recently, Dr. Fried is co-principal investigator of the HCV-TARGET international network studying HCV therapies used in usual clinical practice and co-PI of PRIORITIZE, a pragmatic clinical trial of HCV therapeutics.
Dr. Fried is the primary author or co-author on over 200 original publications, reviews, and book chapters concentrated in the field of viral hepatitis. He was inducted into the American Society of Clinical Investigation (ASCI), an honor society for clinical investigators.
Education & Training
Clinical Center at the National Institutes of HealthFellowship, Liver Diseases, 1990 - 1993
SUNY Upstate Medical UniversityFellowship, Gastroenterology, 1987 - 1989
SUNY Upstate Medical UniversityResidency, Internal Medicine, 1984 - 1987
Tel Aviv University SacklerClass of 1984
Certifications & Licensure
NY State Medical License 1984 - Present
NC State Medical License 1998 - 2026
GA State Medical License 1993 - 1999
MD State Medical License 1989 - 1994
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Gastroenterology
Awards, Honors, & Recognition
- President American Association for the Study of Liver Diseases (AASLD), 2019
- President-Elect American Association for the Study of Liver Diseases (AASLD), 2018
- America's Top Doctors Castle Connolly, 2012-2018
Clinical Trials
Publications & Presentations
PubMed
- 9 citationsHepatic real-world outcomes with obeticholic acid in primary biliary cholangitis (HEROES): A trial emulation study design.M Alan Brookhart, Tracy J Mayne, Charles Coombs, Alexander Breskin, Erik Ness
Hepatology. 2025-06-01 - DAA-PASS: A Prospective Evaluation of HCC Recurrence After Direct Acting Antiviral Therapy.Amit G Singal, K Rajender Reddy, Massimo Colombo, Heather L Morris, Andrea R Mospan
Journal of Viral Hepatitis. 2025-02-01 - 9 citationsReview article: New developments in biomarkers and clinical drug development in alpha-1 antitrypsin deficiency-related liver disease.Rohit Loomba, Ginger Clark, Jeff Teckman, Veeral Ajmera, Cynthia Behling
Alimentary Pharmacology & Therapeutics. 2024-05-01
Journal Articles
- A Comprehensive Assessment of Patient Reported Symptom Burden, Medical Comorbidities, and Functional Well Being in Patients Initiating Direct Acting Antiviral Therapy ...Souvik Sarkar, Michael W. Fried, Richard K. Sterling, Paul W. Stewart, Nancy Reau, Joseph K. Lim, David R. Nelson, Marina Serper, PLoS One
Press Mentions
Target RWE at EASL 2025: Advancing HCC, MASH & PBC ResearchMay 9th, 2025
Target RWE Unveils Latest Developments in TARGET-Liver Disease and Cirrhosis Quality Collaborative Partnership with the American Association for the Study of Liver DiseasesNovember 18th, 2024
Target RWE Announces the Launch of Engage™ - an Innovative, Digital Patient-Centric Engagement PlatformAugust 21st, 2024
Grant Support
- Mentoring Junior Faculty: Viral Hepatitis Clinical ResearchNational Institute Of Diabetes And Digestive And Kidney Diseases2010–2012
- The North Carolina Hepatitis Beta Clinical Research NetworkNational Institute Of Diabetes And Digestive And Kidney Diseases2008–2011
- Division Of Digestive Diseases Serum And Tissue BankNational Center For Research Resources2008
- A Phase I/II Randomized, Placebo Controlled Trial Of Silymarin For Hepatitis CNational Center For Complementary &Alternative Medicine2006–2008
- Mentoring Junior Faculty: Hepatitis C Clinical ResearchNational Institute Of Diabetes And Digestive And Kidney Diseases2004–2008
Committees
- Board Liason, Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD) 2016 - Present
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









